Combination coating of chitosan and anti-CD34 antibody applied on sirolimus-eluting stents can promote endothelialization while reducing neointimal formation

BMC Cardiovascular Disorders

Volumn 12, Issue , 2012, Pages

  Yang, Feng ^a,b   Feng, Shi Chao ^a,b   Pang, Xiang Jun ^c   Li, Wei Xiao ^a,b   Bi, Yong Hua ^a,b   Zhao, Qian ^a   Zhang, Shi Xuan ^e   Wang, Yang ^d   Feng, Bo ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Diagnostic Imaging and Interventional Radiology   (China)

^c Fei Cheng Hospital of Traditional Chinese Medicine   (China)

^d GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^e DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Anti CD34 antibody; Endothelial progenitor cells; Hyaluronan and chitosan coating; Scanning electron microscopy

Indexed keywords

CD34 ANTIBODY; CHITOSAN; CYPHER; HYALURONIC ACID; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; ENDOTHELIUM CELL; HISTOPATHOLOGY; IN-STENT RESTENOSIS; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SWINE;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; ANTIGENS, CD34; CHITOSAN; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; MICROSCOPY, ELECTRON, SCANNING; NEOINTIMA; SIROLIMUS; SWINE;

EID: 84867803261     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-12-96     Document Type: Article

References (28)

1. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with baremetal stents. N Engl J Med 2007, 356:989-997. 10.1056/NEJMoa066633, 17296825.
2. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007, 356:1009-1019. 10.1056/NEJMoa067722, 17296822.
3. Nakazawa G, Tanabe K, Aoki J, et al. Sirolimus-Eluting Stents Suppress Neointimal Formation Irrespective of Metallic Allergy. Circ J 2008, 72:893-896. 10.1253/circj.72.893, 18503212.
4. Lakshmana K, Pendyala, Xinhua Y, et al. The First-Generation Drug-Eluting Stents and Coronary Endothelial Dysfunction. J Am Coll Cardiol Intv 2009, 2:1169-1177.
5. van den Heuvel M, Sorop O, Batenburg WW, et al. Specific Coronary Drug-Eluting Stents Interfere With Distal Microvascular Function After Single Stent Implantation in Pigs. J Am Coll Cardiol Intv 2010, 3:723-730.
6. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202. 10.1016/j.jacc.2006.03.042, 16814667.
7. Curcio A, Torella D, Indolfi C. Mechanisms of Smooth Muscle Cell Proliferation and Endothelial Regeneration After Vascular Injury and Stenting. Circ J 2011, 75:1287-1296. 10.1253/circj.CJ-11-0366, 21532177.
8. van Beusekom HM, Serruys PW. Drug-Eluting Stent Endothelium. J Am Coll Cardiol Intv 2010, 1:76-77.
9. Klomp M, Beijk MA, de Winter RJ. Genous endothelial progenitor cell-capturing stent system: a novel stent technology. Expert Rev Med Devices 2009, 6:365-375. 10.1586/erd.09.16, 19572791.
10. Gaku N, Granada JF, Alviar CL, et al. Anti-CD34 Antibodies Immobilized on the Surface of Sirolimus-Eluting Stents Enhance Stent Endothelialization. J Am Coll Cardiol Intv 2010, 3:68-75.
11. Rossi ML, Zavalloni D, Gasparini GL, et al. The first report of late stent thrombosis leading to acute myocardial infarction in patient receiving the new endothelial progenitor cell capture stent. Int J Cardiol 2010, 141:e20-e22. 10.1016/j.ijcard.2008.11.134, 19135746.
12. Meng S, Liu Z, Shen L, et al. The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. Biomaterials 2009, 30(12):2276-2283. 10.1016/j.biomaterials.2008.12.075, 19168214.
13. Van Der Giessen WJ, Regar E, Harteveld MS, et al. " Edge Effect" of (32)p radioactive stents is causes by the combination of chronic stent injury and radioactive dose falloff. Circulation 2001, 104:2236-2241. 10.1161/hc4301.097873, 11684637.
14. Derkx P, Nigg AL, Bosman FT, et al. Immunolocalization and quantification of noncollagenous bone matrix proteins in methylmethacry-late-embedded adult human bone in combination with histomorphometry. Bone 1998, 22:367-373. 10.1016/S8756-3282(97)00299-8, 9556137.
15. Co M, Tay E, Lee CH, et al. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am Heart J 2008, 155:128-132. 10.1016/j.ahj.2007.08.031, 18082503.
16. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: The HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005, 45:1574-1579. 10.1016/j.jacc.2005.01.048, 15893169.
17. Miglionico M, Patti G, D'Ambrosio A, et al. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: A prospective single-center registry in high-risk patients. Catheter Cardiovasc Interv 2008, 71:600-604. 10.1002/ccd.21437, 18360849.
18. Meng S, Liu Z, Zhong W, et al. Phosphorylcholine Modified Chitosan:Appetent and Safe material for Cell. Carbohydr Polym 2007, 70:82-88.
19. Yin M, Yuan Y, Liu C, et al. Combinatorial coating of adhesive polypeptide and anti-CD34tibody for improved endothelial cell adhesion and proliferation. J Mater Sci: Mater Med 2009, 20:1513-1523.
20. Celik T, Iyisoy A, Kursaklioglu H, et al. The forgotten layer of in-stent restenosis: Endothelial dysfunction. Int J Cardiol 2008, 126:443-444. 10.1016/j.ijcard.2007.02.050, 17466392.
21. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008, 52:333-342. 10.1016/j.jacc.2008.04.030, 18652940.
22. Chen TG, Chen JZ, Wang XX. Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif 2006, 39:117-125. 10.1111/j.1365-2184.2006.00375.x, 16542347.
23. Heleen MM, Oana Sorop M, et al. Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimus-and tacrolimus-eluting stents. Eurointervention 2010, 6:117-125. 10.4244/EIJV6I1A18, 20542807.
24. Butzal M, Loges S, Schweizer M, et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 2004, 300:65-71. 10.1016/j.yexcr.2004.07.002, 15383315.
25. Li JJ, Li J, Nan JL, et al. Coronary restenotic reduction of Drug-eluting stenting may be due to its anti-inflammatory effect. Med Hypotheses 2007, 69(5):1004-1009. 10.1016/j.mehy.2007.01.090, 17499449.
26. Adkins JR, Castresana MR, Wang Z, et al. Rapamycin inhibits release of tumor necrosis factor-alpha from human vascular smooth muscle cells. Am Surg 2004, 70(5):384-387.
27. Higo T, Ueda Y, Oyabu J, et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. J Am Coll Cardiol Img 2009, 2:616-624.
28. Nakazawa G, Vorpahl M, Finn AV, et al. One step forward and two steps back with drug-eluting-stents from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. J Am Coll Cardiol Img 2009, 2:625-628.